At a Glance
- Company: Xenon Pharmaceuticals (Nasdaq: XENE)
- Location: Burnaby, BC, Canada
- Headline figures: -53.2% MPC seizures (25 mg) vs -10.4% placebo; shares +50%
- Focus area: Focal onset seizures (FOS) via KV7 modulation
- Next steps: NDA Q3 2026; AAN presentation April
What happened?
Xenon Pharmaceuticals announced positive topline data from the Phase 3 X-TOLE2 trial of azetukalner on 9 March 2026, showing the KV7 potassium channel opener met its primary endpoint with highly statistically significant seizure reduction in focal onset seizures. The 25 mg dose achieved -53.2% median percent change (MPC) from baseline in monthly FOS frequency versus -10.4% for placebo (p=0.000000000006), outperforming Phase 2b results. Shares surged nearly 50% on the news.
Why does it matter?
Focal onset seizures affect 60% of 3M+ US epilepsy patients with high unmet need; azetukalner’s placebo-adjusted -42.7% MPC represents the strongest pivotal efficacy ever reported, with no titration needed and once-daily dosing. Clean safety (dizziness 15.5%, headache 8%) positions it as potential best-in-class versus Xcopri/Cenobamate, targeting $3B+ add-on market.
Who’s behind it?
Xenon focuses on CNS disorders; CEO Ian Mortimer called results “highest placebo-adjusted efficacy… to date.” Epilepsy KOL Jacqueline French highlighted KV7’s unique profile.
How was it achieved?
X-TOLE2 randomised 380 refractory FOS patients (median 12.75 seizures/month, 5 prior ASMs) to 15/25 mg azetukalner vs placebo. Key secondary RR50 hit 54.8% (25 mg) vs 20.8% placebo (p=0.00008). Safety consistent with Phase 2b; low serious TEAEs across arms.
What’s next?
NDA filing Q3 2026; full data at AAN April 2026. Open-label extension ongoing (322/332 completers). Expand to MDD/bipolar (XNOVA/XCEED) and PGTCS trials.
What are people saying?
CEO Mortimer: “Surpassed expectations… reinforces confidence.” Dr French: “No titration, once-daily… sets it apart.”